Daryl L. Davies, PhD
Associate Dean for Undergraduate Education
Professor of Clinical Pharmacy
Regulatory and Quality Sciences
- Drugs of Abuse Pharmacology and Toxicology
- Early Stage Drug Discovery and Development
- Drug Safety Pharmacology and Toxicology
- Neuro-degenerative Disorders
- Neuro-psychiatric Disorders
MA 1992 Biology (Emphasis Molecular Biology) - California State University, Dominguez Hills
Ph.D. 1996 Molecular Pharmacol & Toxicology - University of Southern California, School of Pharmacy
Dr. Davies is the Associate Dean for Undergraduate Education and a Professor in the Titus Family Department of Clinical Pharmacy at the School of Pharmacy. In his capacity of Associate Dean, he is responsible for the ongoing development and management of the School's undergraduate Major: "Pharmacology and Drug Development," as well as the Minor: "Science and Management of Biomedical Therapeutics." Dr. Davies is also the Director of the MS program in Management of Drug Development (Dept of Regulatory and Quality Sciences) at the School of Pharmacy and undergraduate faculty adviser for the School of Pharmacy Trojan Admission Pre-Pharmacy (TAP) Program. He also is the Director of the STAR program, a cooperative venture in science education between the University of Southern California Health Sciences Campus and Francisco Bravo Medical Magnet High School in East Los Angeles.
In addition to his educational activities, Dr. Davies leads a research team at USC where his laboratory is working to discover and develop novel therapeutics for the treatment of neurodegenerative diseases and alcoholism. He is considered a Pioneer by his peers in the field of purinergic receptors and their role in CNS regulation of alcohol-induced changes in alcohol intake and signaling.
Dr. Davies is a firm believer in using an interdisciplinary approach. To this end, his group works with a team of collaborators which use a combination of pharmacological, toxicological, electrophysiological, molecular, computational chemistry, molecular modeling and regulatory expertise to discover and develop new drugs.
Current collaborative projects: 1) Investigations with Drs. Stan Louie, Liana Asatryan, Jing Liang, Kathy Rodgers and Eunjoo Pacifici (Pharmacy), Michael Jakowec and Daniel Holschneider (KECK) and Marco Bortolato (University of Utah). Dr. Davies, with this team of investigators is undertaking efforts to support a drug discovery program using ivermectin (IVM) as the lead compound for the development of novel P2X4 positive allosteric modulators. The long term translational aspects of this project focus on the development of therapeutic treatment strategies for the treatment of AUD. Dr. Davies' research is primarily funded by National Institute of Alcohol Abuse and Alcoholism (NIAAA). As a major step in this process, Dr. Davies' group has recently reported that Moxidectin (MOX), an IVM analogue, has lower neurotoxicity potential and improved margin of safety compared to IVM. In that MOX is currently becoming approved for human use for other indications (anti-parasitic), Dr. Davies' group is looking to repurpose MOX as a novel pharmacotherapy for AUD.
2) In collaboration with Dr. Jakowec, the Davies group is using a P2X4KO mouse model as a tool for the investigation of changes in signaling pathways that have been linked to neuro-developmental disorders such as autism spectrum disorder, fragile X syndrome and schizophrenia. This line of investigation stems from recent findings suggesting that knocking out the p2rx4 gene (P2XKO model) leads to significant changes in glutamate receptor (i.e., NMDARs and AMPARs) expression across several different brain regions. Building evidence indicates that changes in glutamate expression and function have been associated with gene transcription and protein translation linked to neurodevelopmental issues.
3) In collaboration with Dr. Jakowec, a new avenue of research that proposes to investigate the potential role of experience-dependent neuroplasticity as a therapeutic target in treating AUD as well as other neuro-degenerative diseases including Parkinson?s disease is developing. Studies in this effort have brought together the expertise of the two groups together resulting in a novel and innovative set of studies.
4) Investigations with Drs. Asatryan and Liang (faculty in the Davies laboratory) are focusing on investigating the action of alcohol on GABAA and, Glycine receptors. The long term goal of this work focuses on the development of pharmacotherapeutic treatment strategies for the treatment of alcohol abuse and alcoholism. This collaborative effort is also being supported by collaborations with Drs. James Trudell (Stanford University) and Gregg Homanics (University of Pittsburg). Together this effort is resulting in new molecular models of alcohol action and a new line of transgenic animals that will provide novel methods of investigation into brain region specificity of alcohol action. Interestingly, during the course of these efforts, we identified a novel brain mapping technique that will be useful to the neuroscience and alcohol research communities.
5) Investigations with Drs. Liang and Holschneider are resulting in the development of a series of neutraceuticals for the treatment of anxiety disorders. Notably, anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults in the United States age 18 and older (18% of U.S. population) and have been estimated to consume almost one-third of the country?s mental health bill in excess of $42 billion a year. Currently, there are a number of clinically effective treatments for anxiety and associated psychiatric conditions, but unfortunately, a large segment of patient?s exhibit treatment-resistance to first-line interventions or substantial side effects due to the drugs illustrating the critical need for new pharmacotherapies for the treatment of anxiety.
6) In collaboration with Dr. Frances Richmond (Dept of Regulatory and Quality Sciences), Dr. Davies directs the Masters program in Management of Drug Development. The MS program in the Management of Drug Development at USC is a novel degree program designed for students with a background in preclinical biological and/or pharmaceutical sciences. It aims at producing entry- and mid-level practitioners with the knowledge and skills appropriate for professional practice in translational research, with particular emphasis on the area of transition between early stage preclinical drug discovery and clinical drug development. This area, commonly referred to as the "valley of death," represents one of the most challenging and important areas in translational research, yet programs designed to train and educate future translational science leaders are lacking.
2019 - present: Associate Dean for Undergraduate Education
2016 - 2019: Director of Undergraduate Education
2016 - present: Faculty advisor for undergraduate Pre-Pharmacy club and Director of TAP program
2016 - present: Director of Bravo High School STAR program. A cooperative venture in science education between the USC Health Sciences Campus and Francisco Bravo Medical Magnet High School in East Los Angeles.
2015 - present: Professor, Titus Dept. of Clinical Pharmacy, School of Pharmacy, University of Southern California.
2011 - present: Director, Management of Drug Development Master's Program, Dept of Regulatory and Quality Sciences
2008-2015: Associate Professor of Clinical Pharmacy, Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, School of Pharmacy, University of Southern California.
2005-2008: Research Associate Professor, Molecular Pharmacology and Toxicology, School of Pharmacy, University of Southern California.
1999-2005: Research Assistant Professor, Molecular Pharmacology and Toxicology, School of Pharmacy, University of Southern California.
1997-present: Director, Alcohol and Brain Research Lab, School of Pharmacy, University of Southern California, Los Angeles, California
1996: Post Doctoral Research Associate, Alcohol and Brain Research Lab, School of Pharmacy, University of Southern California, Los Angeles, California.
1996: University of Southern California, School of Pharmacy, -- Ph.D. Molecular Pharmacology and Toxicology. Dissertation Title: Do Allosteric Coupling Pathways for the Benzodiazepine, Barbiturate and Neuroactive Steroid Recognition Sites on the GABA-A Receptor Represent Initial Sites of Action for Ethanol? Mentor: Ronald L. Alkana, Pharm.D., Ph.D.
1992: California State University, Dominguez Hills, M.A. -- Biology (Emphasis in Molecular Biology).
1990: CSU, Dominguez Hills, Carson, California-B.A. -- Biology with honors.
Sigma Xi, 1991-present
Research Society on Alcoholism, 1993-present
Society for Neuroscience, 1994-present
International Society for Biomedical Research on Alcoholism, 1996-present
Drug Information Association, 1996-present
American Society for Pharmacology and Experimental Therapeutics, 1997-present
2018-2022 NIH/Neurotoxicology and Alcohol Study Section (NAL) Standing member
2017 NIH/Neurotoxicology and Alcohol Study Section (NAL); invited reviewer
2015 NIH/Blueprint for Neurotherapeutics network (BNP) ZNS1 SRB-T Special emphasis panel.
2014 NIH/National Center for Advancing Translational Sciences (NCATS). USC CTSI Mock F31 grant reviewer.
NIH/NCATS Special Emphasis Panel/Scientific Review Group 2013/05 ZTR1 DPI-6 (01)
2012 NIH/NCATS (The National Center for Advancing Translational Sciences). USC CTSI Reviewed Therapeutic Discovery pilot applications in 2012.
2011- present USC – CTSI pilot grant reviewer
2013-present SC CTSI's KL2 and TL1 Training Program grant reviewer
2015-present USC Rose Hills Fellowship
2013 US Army Medical Research and Materiel Command—Alcohol/Drug Abuse: Neurobiology-Therapy Panel
Ad hoc reviewer for other DoD proposals in the PRMRP program
Ad hoc reviewer for South Carolina Experimental Program to Stimulate Competitive Research (EPSCoR) and Institutional Development Awards (IDeA) programs.
Huynh N, Arabian NM, Asatryan L, Davies DL. Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice. J Vis Exp. 2019 Jan 7;(143). PubMed -Link
Khoja S, Shah V, Garcia D, Asatryan L, Jakowec MW, Davies DL. Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors. J Neurochem. 2016 Jul 12. doi: 10.1111/jnc.13734. PubMed -Link
Asatryan L, Khoja S, Rodgers KE, Alkana RL, Tsukamoto H, Davies DL. Chronic ethanol exposure combined with high fat diet up-regulates P2X7 receptors that parallels neuroinflammation and neuronal loss in C57BL/6J mice. J Neuroimmunol. 2015 Aug 15;285:169-79. PubMed -Link
Huynh N, Arabian N, Lieu D, Asatryan L, Davies DL Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals. J Vis Exp. 2016 Mar 23;(109):e53770. PubMed -Link
Franklin K.M., Asatryan L., Jakowec M.W., Trudell J.R., Bell R.L. and Davies D.L. P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders. Front Neurosci. 2014 Review. PubMed
Davies DL, Bortolato M, Finn DA, Ramaker MJ, Barak S, Ron D, Liang J and Olsen RW. Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders, Alcohol Clin Exp Res, 37: 8-15, 2013PubMed
Wyatt L.R., Godar S.C., Khoja S., Jakowec M.W., Alkana R.L., Bortolato M. and Davies D.L. Socio-communicative and sensorimotor impairments in male P2X4-deficient mice. Neuropsychopharmacology. 2013 38:1993-2002.PubMed
Yardley M, Wyatt L, Khoja S, Asatryan L, Ramaker MJ, Finn DA, Alkana RL, Huynh N, Louie SG, Petasis, NA, Bortolato M and Davies DL. Ivermectin Reduces Alcohol intake and preference in Mice. Neuropharmacology, 63:190-201, 2012 PubMed
Bortolato M, Yardley M, Khoja S, Godar SC, Asatryan L, Finn DA, Huynh N, Alkana RL, Louie SG and Davies DL. Pharmacological insights into the role of P2X4 receptors in behavioral regulation: lessons from ivermectin, Int J Neuropsychopharmacology, 2013 16:1059-1070.PubMed
Asatryan L,Popova M,Perkins D,Trudell JR,Alkana RL,Davies DL -Ivermectin antagonizes ethanol inhibition in purinergic P2X4 receptors.- J Pharmacol Exp Ther  Sep 1;334(3):720-8 PubMed